WASHINGTON/NEW YORK (Reuters)—U.S. Senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at the start of a Senate hearing on the rising costs of prescription medicines. Executives from Abbvie Inc., AstraZeneca PLC., Sanofi SA, Pfizer…
Articles by Natasha Yetman
Ibuprofen an Option for Early Pain Control after Hip Replacement
NEW YORK (Reuters Health)—Combining paracetamol (acetaminophen) with ibuprofen does not cut postoperative use of morphine in a clinically meaningful way relative to ibuprofen alone, in patients undergoing total hip arthroplasty (THA), results of a Danish randomized trial suggest. “Although the combined use of paracetamol and ibuprofen reduced immediate postoperative morphine consumption compared with paracetamol alone…
U.S. Government Proposes Rule Overhauling Drug Industry Rebate System
NEW YORK (Reuters)—The U.S. government proposed a rule to end the industry-wide system of after-market discounts called rebates that pharmacy benefit managers receive from drugmakers, a practice that has been under scrutiny. If finalized, the rule would change a system that has been in place for decades and that increasingly has been criticized for obfuscating…
U.S. Judge Throws Out Maryland Bid to Protect Obamacare
WASHINGTON (Reuters)—On Feb. 1, a U.S. judge threw out the state of Maryland’s bid to protect the healthcare law, known as Obamacare, in a ruling that also sidestepped a decision on whether President Donald Trump’s appointment of Matthew Whitaker as acting attorney general was lawful. In a win for the Republican president, Baltimore-based U.S. District…
U.S. Senate Finance Committee Invites Pharma Execs to Testify
WASHINGTON (Reuters)—A powerful U.S. Senate committee on has invited seven pharmaceutical companies to testify at a hearing later this month examining rising prescription drug prices. Sen. Chuck Grassley (R-IA), chairman of the Senate Finance Committee, and Sen. Ron Wyden (D-Ore.), ranking member of the committee, invited executives from AbbVie Inc., AstraZeneca PLC, Bristol-Myers Squibb Co.,…
RA Effectiveness Differs Among Non-TNF Inhibitors
NEW YORK (Reuters Health)—Rheumatoid arthritis (RA) outcomes are better with some non-TNF inhibitors than with others, according to French registry data. “Previously, indirect comparisons (meta-analyses) did not show any difference between biologics in terms of effectiveness,” Dr. Jacques-Eric Gottenberg from Strasbourg University Hospital, France, tells Reuters Health by email. “Our direct comparison using observational data…
Walking Ability of OA Patients Linked to Cardiovascular Risk
New research explores the association of the ability to walk and the risk of cardiovascular disease in OA patients compared with the general population. During the study, researchers recorded a six-minute walking distance and measured arterial stiffness of participants. The results: Even among younger people, OA patients could not walk as far as those in the general population. Also, arterial stiffness was inversely associated with walking distance, suggesting walking is important to the cardiovascular risk profile of OA patients…
What Do JIA Patients Experience? A New Case Study from the ARP Practice Committee
What does a new patient experience as symptoms develop and diagnosis is confirmed? The ARP Practice Committee is developing persona-based case studies to help answer this and other questions. The latest topic is juvenile idiopathic arthritis…
New EPA Rule May Hinder Health Research
(Reuters Health)—A new rule proposed by the U.S. Environmental Protection Agency (EPA) may make it almost impossible to uncover hazards such as dirty air, polluted water and environmental toxins, researchers say. The rule mandates that all underlying data from studies be made available to any and all researchers in the interests of transparency. But while…
Medicare Changes Could Have Some Patients Paying More for Drugs
(Reuters Health)—A proposed shift in Medicare coverage for medicines administered by doctors may help reduce total drug spending, but a new study suggests it may also lead to higher out-of-pocket costs for some patients. Right now, drugs given by infusion or injection in outpatient settings are covered by Medicare Part B, which is part of…
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 97
- Next Page »